RNAC
Price
$7.36
Change
+$0.14 (+1.94%)
Updated
Oct 2 closing price
Capitalization
218.14M
33 days until earnings call
Intraday BUY SELL Signals
VBIO
Price
$2.59
Change
+$0.08 (+3.19%)
Updated
Oct 2 closing price
Capitalization
2.4M
Intraday BUY SELL Signals
Interact to see
Advertisement

RNAC vs VBIO

RNAC vs VBIO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
RNAC vs. VBIO commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RNAC is a Hold and VBIO is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
RNAC vs VBIO: Fundamental Ratings
RNAC
VBIO
OUTLOOK RATING
1..100
692
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6496
P/E GROWTH RATING
1..100
3368
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VBIO's Valuation (80) in the null industry is in the same range as RNAC (98) in the Biotechnology industry. This means that VBIO’s stock grew similarly to RNAC’s over the last 12 months.

VBIO's Profit vs Risk Rating (98) in the null industry is in the same range as RNAC (100) in the Biotechnology industry. This means that VBIO’s stock grew similarly to RNAC’s over the last 12 months.

VBIO's SMR Rating (100) in the null industry is in the same range as RNAC (100) in the Biotechnology industry. This means that VBIO’s stock grew similarly to RNAC’s over the last 12 months.

RNAC's Price Growth Rating (64) in the Biotechnology industry is in the same range as VBIO (96) in the null industry. This means that RNAC’s stock grew similarly to VBIO’s over the last 12 months.

RNAC's P/E Growth Rating (33) in the Biotechnology industry is somewhat better than the same rating for VBIO (68) in the null industry. This means that RNAC’s stock grew somewhat faster than VBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RNACVBIO
RSI
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 9 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (RNAC: $7.36 vs. VBIO: $2.59)
Brand notoriety: RNAC and VBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RNAC: 158% vs. VBIO: 21%
Market capitalization -- RNAC: $218.14M vs. VBIO: $2.4M
RNAC [@Biotechnology] is valued at $218.14M. VBIO’s [@Biotechnology] market capitalization is $2.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RNAC’s FA Score shows that 1 FA rating(s) are green while VBIO’s FA Score has 0 green FA rating(s).

  • RNAC’s FA Score: 1 green, 4 red.
  • VBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, RNAC is a better buy in the long-term than VBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RNAC’s TA Score shows that 4 TA indicator(s) are bullish while VBIO’s TA Score has 4 bullish TA indicator(s).

  • RNAC’s TA Score: 4 bullish, 6 bearish.
  • VBIO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both RNAC and VBIO are a bad buy in the short-term.

Price Growth

RNAC (@Biotechnology) experienced а -0.67% price change this week, while VBIO (@Biotechnology) price change was -14.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.69%. For the same industry, the average monthly price growth was -14.41%, and the average quarterly price growth was -1.73%.

Reported Earning Dates

RNAC is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
RNAC
Daily Signal:
Gain/Loss:
VBIO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SKM35.590.68
+1.95%
SK Telecom Co Ltd
GAU1.950.01
+0.52%
Galiano Gold
YDDL1.42N/A
N/A
One and one Green Technologies Inc
FRME39.58-0.20
-0.50%
First Merchants Corp
JTAI1.52-0.02
-1.62%
Jet.AI Inc.

VBIO and

Correlation & Price change

A.I.dvisor tells us that VBIO and SNGX have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VBIO and SNGX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VBIO
1D Price
Change %
VBIO100%
-10.36%
SNGX - VBIO
25%
Poorly correlated
+0.50%
DARE - VBIO
25%
Poorly correlated
-0.27%
ENLV - VBIO
23%
Poorly correlated
-15.93%
BNTC - VBIO
23%
Poorly correlated
-4.20%
RNAC - VBIO
23%
Poorly correlated
+0.14%
More